Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Revivo Therapeutics General Information
Revivo is conducting Phase I clinical trials with its lead candidate RIV‑5061 in healthy volunteers to assess safety, tolerability, pharmacokinetics/pharmacodynamics. The drug acutely enhances cognitive function and reduces anxiety in preclinical models. The company is raising funds for further clinical development.
Contact Information
Primary Industry
Biotech
Corporate Office
Durham, North Carolina
United States
United States
Drug Pipeline
RIV-5061
Pre-clinicalKey Partnerships
NIH, ADDF (Alzheimer's Drug Discovery Foundation), Bioventures Investors have provided funding support.
Revivo Therapeutics Funding
No funding data available
To view Revivo Therapeutics's complete valuation and funding history, request access »